

C2  
8. (AMENDED) The DNA-construct according to claim 1 wherein the hematopoietic cells are megakaryocytes.

C3  
12. (AMENDED) The process according to claim 9 wherein the DNA sequence functioning as a promoter is the DNA sequence for the human platelet glycoprotein IIb (GPIIb) promoter.

13. (AMENDED) The process according to claim 9 wherein the hematopoietic cells are megakaryocytes.

14. (AMENDED) The process according to claim 5 wherein the hematopoietic cells are megakaryocytes.

**REMARKS**

Upon entry of this Amendment and Response, claims 1 to 14 are pending. Claims 2, 8 and 12-14 have been amended to more clearly define the claimed invention. Support for the amendments to claims 2 and 12 can be found in the specification and particularly at page 2, lines 24-26. Support for the amendments to claims 8, 13 and 14 can be found throughout the specification and specifically the Examples beginning at page 5. Accordingly, no new matter has been added. The above amendments and following remarks place the claims in condition for allowance or in better condition for appeal. Applicants, therefore, respectfully request reconsideration in light of these amendments and remarks.

FINNEGAN  
ENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com